Ellington Management Group’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-4,809
| Closed | -$823K | – | 493 |
|
|
2018
Q3 | $823K | Sell |
4,809
-1,443
| -23% | -$247K | 0.22% | 119 |
|
|
2018
Q2 | $808K | Sell |
6,252
-2,885
| -32% | -$373K | 0.06% | 90 |
|
|
2018
Q1 | $941K | Buy |
+9,137
| New | +$941K | 0.07% | 201 |
|
|
2016
Q4 | – | Sell |
-3,206
| Closed | -$204K | – | 678 |
|
|
2016
Q3 | $204K | Buy |
+3,206
| New | +$204K | 0.06% | 535 |
|
|
2016
Q2 | – | Sell |
-3,046
| Closed | -$203K | – | 384 |
|
|
2016
Q1 | $203K | Buy |
+3,046
| New | +$203K | 0.09% | 392 |
|
|
2015
Q3 | – | Sell |
-4,649
| Closed | -$293K | – | 806 |
|
|
2015
Q2 | $293K | Buy |
+4,649
| New | +$293K | 0.07% | 437 |
|
|
2015
Q1 | – | Sell |
-7,855
| Closed | -$261K | – | 757 |
|
|
2014
Q4 | $261K | Buy |
+7,855
| New | +$261K | 0.09% | 370 |
|
|
2013
Q4 | – | Sell |
-34,144
| Closed | -$922K | – | 683 |
|
|
2013
Q3 | $922K | Buy |
+34,144
| New | +$922K | 0.17% | 132 |
|